New drug combo shows promise for Sjogren's sufferers
NCT ID NCT05016297
First seen Mar 23, 2026 · Last updated May 13, 2026 · Updated 7 times
Summary
This study tested whether baricitinib, a drug that calms the immune system, can help people with active Sjogren's syndrome. About 87 adults were randomly assigned to take either hydroxychloroquine alone or baricitinib with or without hydroxychloroquine for 24 weeks. The goal was to see if baricitinib could better reduce symptoms like dryness and fatigue, as measured by standard disease activity scores.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SJOGREN'S SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100730, China
Conditions
Explore the condition pages connected to this study.